Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
FDA approved Revolution Medicines’ daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The pivotal RASolute 302 trial showed a substantial overall-survival benefit in previously treated metastatic disease. However, the public trial descriptions do not establish the label’s “not candidates” group as a separately randomized population—and the available evidence does not establish that Revolution Medicines’ stock is priced for this label or justify a “hold” valuation call.
What RASolute 302 tested—and what it found
RASolute 302 was an international, open-label, randomized Phase 3 trial comparing daraxonrasib with chemotherapy chosen by the investigator. It enrolled patients with metastatic pancreatic ductal adenocarcinoma whose disease had progressed after one prior line of systemic therapy. The trial’s primary evidence is therefore about treatment of previously treated metastatic disease, not every setting now described in the FDA indication.
In the overall trial population, median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. The FDA approval summary reports a hazard ratio of 0.40 (95% confidence interval 0.30–0.53; p<0.0001). These results are also reported in the 2026 New England Journal of Medicine trial publication. Median survival is a group-level trial measure, not a prediction of how long an individual patient will live.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →The NEJM report gives a separate result for the RAS G12 population: median overall survival was 13.2 months with daraxonrasib versus 6.6 months with chemotherapy, with a hazard ratio of 0.40 and P<0.001. That subgroup result should not be substituted for the overall-population result: the chemotherapy median differs, and the two populations are distinct.
#1 Best Overall
Does the FDA label go beyond the reported trial population?
There is a meaningful wording difference. FDA’s approved population covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or adults who are not candidates for multiagent systemic therapy. FDA identifies RASolute 302 as the efficacy study and describes it as a randomized trial in patients whose disease progressed after one prior line of systemic therapy.
The public trial descriptions reviewed here do not establish the “not candidates for multiagent systemic therapy” group as a separately randomized population. That is a boundary of what can be concluded from those descriptions—not evidence that the entire approved population lacks trial support or that FDA approved an unsupported drug. The pivotal randomized evidence supports the approval overall; the precise alternative label wording should not be presented as an independently tested subgroup unless separate evidence establishes that.
Rank #2
What the approval means for first-line pancreatic cancer and other programs
RASolute 302 does not establish efficacy in first-line pancreatic cancer, after surgery, or in lung cancer. Revolution Medicines’ June 2026 filing describes those as separate development programs with their own populations, combinations, and evidence still to generate.
| Program | Setting and comparison described by the company | How to interpret it |
|---|---|---|
| RASolute 303 | First-line metastatic pancreatic ductal adenocarcinoma (PDAC); daraxonrasib with and without chemotherapy versus chemotherapy | A separate Phase 3 test; RASolute 302’s survival result does not establish its outcome. |
| RASolute 304 | Adjuvant daraxonrasib after surgery and chemotherapy | A different treatment setting from metastatic disease. |
| RASolute 305 | First-line metastatic PDAC; zoldonrasib with chemotherapy | A separate candidate and trial, not an extension of the approved drug’s trial result. |
| RASolute 309 | First-line RAS G12D PDAC; daraxonrasib plus zoldonrasib | A distinct combination and mutation-defined program. |
| RASolve 301 | Previously treated RAS-mutant non-small-cell lung cancer (NSCLC); daraxonrasib versus docetaxel | A lung-cancer study with a different disease population. |
The June 2026 filing also describes planned additional trials and company expectations for RASolve 301 enrollment and readout timing. Those expectations are company guidance, can change, and are not trial outcomes. The filing lists daraxonrasib, zoldonrasib (RMC-9805), elironrasib (RMC-6291), and RMC-5127 as clinical-stage RAS(ON) inhibitors. These are investigational candidates, not approved medicines; their mutation targets and development stages should not be treated as interchangeable.
What the company’s finances show—and what they do not
Revolution Medicines reported $3.9 billion in cash, cash equivalents, and marketable securities as of June 30, 2026. The company said the balance included proceeds from April 2026 public offerings and convertible notes, as well as a May 2026 royalty-funding tranche. That reported liquidity provides funding context for development activity; it does not by itself establish a fair share price.
For the second quarter of 2026, the company reported $394.9 million in research and development expense and a net loss of $644.4 million. The net loss included a non-cash $151.0 million warrant fair-value charge. The company updated its full-year 2026 GAAP operating expense guidance to $2.1–$2.2 billion. These are company-reported figures and guidance, not measures of the drug’s eventual commercial value or a forecast of future losses.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Can the stock be called “priced for” the label?
Not from the available information. Establishing that claim requires, at minimum, a current share price and share count or market capitalization, plus a transparent valuation method. The available materials establish approval, trial outcomes, development programs, and recent financial figures, but do not establish a current market value or provide a valuation model. They also do not verify investor consensus. Saying the stock is priced for the approved or broader label would therefore overstate what these facts show.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesA defensible investment assessment would need to weigh the approved indication and its trial evidence separately from uncertain future programs; account for the distinct patient settings and mutation targets in those programs; and evaluate the timing and probability of further trial readouts alongside the company’s spending and financing needs. The strong RASolute 302 result is relevant evidence, but it cannot alone answer whether RVMD is cheap, expensive, or appropriately valued. The evidence here is insufficient to substantiate a “hold” recommendation.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
